Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
Avis Budget Group to Announce Third Quarter 2025 Results on October 27th
04:14pm, Friday, 03'rd Oct 2025
PARSIPPANY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its third quarter 2025 results after the market close on Monday, Octob
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Car-Mart (CRMT) To Contact Him Directly To Discuss Their Options If you purchased or acq
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
07:30am, Thursday, 25'th Sep 2025
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today annou
Hemogenyx Pharmaceuticals shares rise (again) as it inks agreement to commercialise CAR-T
03:42am, Tuesday, 23'rd Sep 2025
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares advanced around 11% after announcing the signing of a letter of intent with Cellin Technologies, to explore the commercialisation of its HG
Hemogenyx rises on progress in CAR-T trial
04:06am, Wednesday, 17'th Sep 2025
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares jumped 26% after the biotech reported encouraging early results from its phase I trial of HG-CT-1, an experimental CAR-T therapy for relapsed
Final Trade: WYNN, CAR, JD, NVO
06:21pm, Monday, 15'th Sep 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
PRINCETON, N.J. and NEW YORK , Sept.
Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif. , Sept. 8, 2025 /PRNewswire/ --
BROAD ARROW PRESENTS ASTON MARTIN VALKYRIE OWNED BY DANIEL RICCIARDO AT ZOUTE CONCOURS AUCTION
10:24am, Wednesday, 03'rd Sep 2025
ASTON MARTIN VALKYRIE HYPERCAR COMMISSIONED BY DANIEL RICCIARDO TO HIS PERSONAL SPECIFICATION | AUCTION TO TAKE PLACE ON 10 OCTOBER 2025 IN COLLABORATION WITH ZOUTE GRAND PRIX CAR WEEK ASTON MARTIN VA
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome
Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing
08:00am, Tuesday, 26'th Aug 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .
Why Investors Slammed the Brakes on Avis Stock Today
06:43pm, Wednesday, 20'th Aug 2025
Shares of Avis Budget Group (CAR -5.54%) coughed and sputtered like a stalling car on Hump Day, shedding almost 6% of their price across the trading session. That was almost entirely due to the news t
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
03:29pm, Wednesday, 20'th Aug 2025
The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of
Avis Budget Stock Falls As Bank of America Warns Weak Demand, Pricing Could Hurt Earnings
01:15pm, Wednesday, 20'th Aug 2025
Avis Budget Group CAR shares are trading lower after BofA Securities analyst Federico Merendi downgraded the stock from Buy to Underperform and cut its price target from $120 to $113.
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
09:00am, Monday, 18'th Aug 2025
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif. , Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:
